| Trial ID: | L5101 |
| Source ID: | NCT00873821
|
| Associated Drug: |
Mk-0941
|
| Title: |
A Pharmacokinetic Study of MK-0941 After Multiple Daily Doses in Subjects With Type 2 Diabetes (MK-0941-012)(COMPLETED)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT00873821/results
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: MK-0941|DRUG: Comparator: Placebo
|
| Outcome Measures: |
Primary: Number of Participants With Any Clinical Adverse Experience, An adverse experience was defined as any unfavorable and unintended change in the structure or function of the body temporally associated with the use of study drug. Adverse experiences were collected using Medical Dictionary for Regulatory Activities (MedDRA) version 13.0., 2 months|Number of Participants With Any Laboratory Adverse Experience, Laboratory adverse experiences were those related to changes in hematology, fasted blood chemistry, or urinalysis laboratory results. Adverse experiences were collected using MedDRA version 13.0., 2 months|Change From Baseline to Day 13 in Weighted Mean Plasma Glucose Concentration, Weighted mean plasma glucose concentration was calculated as the 24-hour area under the plasma concentration-time curve divided by 24, Baseline (predose Day 1) to Day 13 |
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
44
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2008-12
|
| Completion Date: |
2009-05
|
| Results First Posted: |
2012-07-11
|
| Last Update Posted: |
2015-03-09
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00873821
|
